Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. LIMN
stocks logo

LIMN

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Valuation Metrics

The current forward P/E ratio for Liminatus Pharma Inc (LIMN.O) is 0.00, compared to its 5-year average forward P/E of 0.00. For a more detailed relative valuation and DCF analysis to assess Liminatus Pharma Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
0.00
Current PE
0.00
Overvalued PE
0.00
Undervalued PE
0.00

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
Intellectia AI SwingMax
Intellectia AI SwingMax

Financials

Annual
Quarterly
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Financial AI Agent
Financial AI Agent

LIMN News & Events

Events Timeline

(ET)
2025-07-28
07:34:53
Liminatus Pharma to launch 'American BNB Strategy' subsidiary
select
2025-07-25 (ET)
2025-07-25
08:36:36
Liminatus Pharma evaluates formation of digital asset investment vehicle
select
2025-07-24 (ET)
2025-07-24
08:45:25
Liminatus Pharma entered into engagement agreement with Digital Offering
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.5
11-21Benzinga
Dow Rises More Than 200 Points as BJ's Wholesale Reports Strong Q3 Earnings

  • U.S. Stock Market Performance: U.S. stocks rose this morning, with the Dow Jones gaining over 200 points, while the NASDAQ and S&P 500 also saw increases of 0.56%. Communication services stocks led the gains, rising by 1.7%.

  • BJ's Wholesale Club Earnings: BJ's Wholesale Club reported better-than-expected third-quarter earnings, with adjusted EPS of $1.16, surpassing estimates. The company raised its fiscal 2025 EPS guidance to a range of $4.30 to $4.40.

  • Notable Stock Movements: Iveda Solutions saw a 63% increase in shares after announcing a new partnership in Egypt, while Nuvve Holding Corp and OSR Holdings also experienced significant gains. Conversely, Liminatus Pharma and authID Inc faced notable declines.

  • Global Market Trends: European and Asian markets closed lower, with the eurozone's STOXX 600 down 0.4% and Japan's Nikkei 225 falling 2.40%. Commodity prices showed mixed results, with oil down 1.8% and gold slightly up.

[object Object]
Preview
7.5
10-30Newsfilter
Liminatus Pharma, Inc. (NASDAQ: LIMN) Enters MOU with Capital Trust Group for $30 Million Equity Investment Through Earn-Out Structure and Future Strategic Partnership

  • Liminatus Pharma's MOU with CTG: Liminatus Pharma has signed a Memorandum of Understanding with Capital Trust Group for a USD 30 million equity financing to support its immunotherapy research and development.

  • Investment Details: The investment is contingent on due diligence and the negotiation of definitive agreements, with plans to finalize these agreements in November 2025.

  • Future Cooperation: Alongside the equity investment, discussions for further strategic cooperation, including potential digital bond financing programs, are set to begin in mid-November.

  • Company Background: Liminatus Pharma focuses on developing next-generation immuno-oncology therapies, while CTG is a New Zealand-based investment management firm involved in large-scale financing across various sectors.

[object Object]
Preview
8.5
07-28Newsfilter
Liminatus Pharma Inc. to Launch "American BNB Strategy" Subsidiary and Target Up To $500 Million Fund for BNB Investment as Part of Crypto Market Initiative

  • Company Expansion into Cryptocurrency: Liminatus Pharma, Inc. plans to establish a subsidiary called "American BNB Strategy" to invest up to $500 million in BNB coin, aiming for long-term growth while maintaining its focus on cancer therapeutics.

  • Strategic Investment Approach: The company emphasizes that this initiative is not speculative but based on the robust technology and potential of the BNB ecosystem, with security measures provided by Ceffu to ensure compliance and integrity in their digital asset investments.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Liminatus Pharma Inc (LIMN) stock price today?

The current price of LIMN is 0.953 USD — it has decreased -2.76 % in the last trading day.

arrow icon

What is Liminatus Pharma Inc (LIMN)'s business?

Liminatus Pharma, Inc. is a pre-clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies. The Company is engaged in the development of a second generation CD47 blockade antibody designed to prevent the induction of severe anemia and thrombocytopenia observed with first generation CD47 blockades. The Company’s candidate, IBA101, is a humanized anti-CD47 monoclonal antibody. The CD47 checkpoint inhibitor’s initial indication is expected to be patients with advanced solid cancers, including non-small cell lung cancer. IBA101 is a humanized anti-human CD47 monoclonal antibody with a human IgG4 Fc, designed to preferentially bind nucleated cells, such as immune and tumor cells, while sparing anucleate cells like red blood cells and platelets. IBA101 promotes macrophage-mediated phagocytosis of tumor cells.

arrow icon

What is the price predicton of LIMN Stock?

Wall Street analysts forecast LIMN stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for LIMN is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Liminatus Pharma Inc (LIMN)'s revenue for the last quarter?

Liminatus Pharma Inc revenue for the last quarter amounts to -701.17K USD, increased 29.06 % YoY.

arrow icon

What is Liminatus Pharma Inc (LIMN)'s earnings per share (EPS) for the last quarter?

Liminatus Pharma Inc. EPS for the last quarter amounts to -613720.00 USD, decreased % YoY.

arrow icon

What changes have occurred in the market's expectations for Liminatus Pharma Inc (LIMN)'s fundamentals?

The market is revising No Change the revenue expectations for LIMN for , with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -64.31%.
arrow icon

How many employees does Liminatus Pharma Inc (LIMN). have?

Liminatus Pharma Inc (LIMN) has 0 emplpoyees as of December 05 2025.

arrow icon

What is Liminatus Pharma Inc (LIMN) market cap?

Today LIMN has the market capitalization of 25.79M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free